摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

去乙基利多卡因 | 7728-40-7

中文名称
去乙基利多卡因
中文别名
盐酸单乙基甘氨酸二甲基苯胺;利多卡因杂质D
英文名称
N-(2,6-dimethylphenyl)-2-ethylaminoacetamide
英文别名
MEGX;monoethylglycinexylidide;Monoethylglycinxylidid;Norlidocaine;N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide
去乙基利多卡因化学式
CAS
7728-40-7
化学式
C12H18N2O
mdl
MFCD00098991
分子量
206.288
InChiKey
WRMRXPASUROZGT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    242-245°C
  • 沸点:
    335.6±30.0℃ (760 Torr)
  • 密度:
    1.047±0.06 g/cm3 (20 ºC 760 Torr)
  • 闪点:
    127.8±24.7℃
  • 溶解度:
    在水中的溶解度为10mg/mL,澄清
  • 保留指数:
    1783.5

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    41.1
  • 氢给体数:
    2
  • 氢受体数:
    2

ADMET

代谢
单乙基甘氨酸乙酯已知的人类代谢物包括甘氨酸乙酯和3-羟基单乙基甘氨酸乙酯。
Monoethylglycinexylidide has known human metabolites that include Glycinexylidide and 3-Hydroxymonoethyl glycinexylidide.
来源:NORMAN Suspect List Exchange

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S45
  • 危险类别码:
    R22
  • WGK Germany:
    1,3
  • 海关编码:
    2924299090
  • 危险标志:
    GHS06
  • 危险性描述:
    H301
  • 危险性防范说明:
    P301 + P310
  • 储存条件:
    2-8°C

SDS

SDS:403c90f6d7b4b38a510b36281a077933
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : MEGX
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 7728-40-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Synonyms : N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide
Monoethylglycinexylidide
Norlidocaine
Formula : C12H18N2O
Molecular Weight : 206,28 g/mol
CAS-No. : 7728-40-7
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
MEGX
CAS-No. 7728-40-7 Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
MEGX
CAS-No. 7728-40-7 Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Store with desiccant.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point not applicable
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,744
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
LD50 Oral - mouse - 234 mg/kg
Remarks: Behavioral:Convulsions or effect on seizure threshold.
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (MEGX)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (MEGX)
IATA: Toxic solid, organic, n.o.s. (MEGX)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

单乙基甘氨酰亚胺是利多卡因(HY-B0185)在肝脏中经细胞色素P-450酶催化氧化去乙基后生成的代谢产物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    去乙基利多卡因 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 24.0h, 生成 lidocaine
    参考文献:
    名称:
    2, 6 XYLIDINE DERIVATIVES FOR THE TREATMENT OF PAIN
    摘要:
    本公开提供了一种化合物的组成,其化学式为1。本公开还提供了一种合成化学式1的方法。化学式1的化合物或其药用可接受的盐,以及其多晶形、溶剂合物和水合物可以配制为用于治疗疼痛的药物组合物。化学式1的化合物或最终化合物的药物组合物可以配制为非侵入性口服、局部(例如经皮)、肠内、经粘膜、靶向递送、持续释放递送、延迟释放、脉冲释放和肠外方法。这些组合物可用于治疗伴有慢性疾病或其相关并发症的慢性疼痛。化学式1的化合物也可以作为一种套装提供。
    公开号:
    US20120022147A1
  • 作为产物:
    描述:
    盐酸利多卡因 在 glucose dehydrogenase 、 葡萄糖 、 cytochrome P450BM3 R47L/Y51F/F81W/F87V/E267V/I401P mutant 、 NADP+ monosodium salt 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以85%的产率得到去乙基利多卡因
    参考文献:
    名称:
    细胞色素P450BM3氧化药物:代谢产物的合成和发现新的P450反应类型
    摘要:
    后期催化CH键功能化作为合成不可或缺的一部分引起了人们极大的兴趣。有效的催化剂必须具有广泛的底物范围,并能耐受各种官能团。药物分子可以很好地测试催化剂的这些属性。P450 BM3库由对碳氢化合物具有高活性的四个碱基突变体开发的突变体产生了一系列药物的人类代谢产物,其中包括中性(氯唑沙宗,睾丸激素),阳离子(阿米替林,利多卡因)和阴离子(双氯芬酸,萘普生)化合物。没有一个突变体对所有测试药物都具有活性,但是文库中的多个变体对每种化合物均显示出高活性。高转化率可实现完整的产品表征,从而导致发现了新的P450反应类型,即α-羟基羧酸的氧化脱羧反应,并形成了受胺保护的亚胺,为胺的α-官能化提供了一条新途径。底物范围和不同的产物谱表明该酶库是开发晚期C的良好基础H活化催化剂。
    DOI:
    10.1002/chem.201502020
点击查看最新优质反应信息

文献信息

  • Structural elucidation of amino amide‐type local anesthetic drugs and their main metabolites in urine by LC‐MS after derivatization and its application for differentiation between positional isomers of prilocaine
    作者:Avi Weissberg、Eyal Drug、Hagit Prihed、Moran Madmon、Tamar Shamai Yamin
    DOI:10.1002/jms.4654
    日期:2020.10
    ambient temperature followed by LC‐ESI‐MS/MS analysis was developed. 2,2,2‐Trichloro‐1,1‐dimethylethyl chloroformate (TCDMECF) was utilized to selectively convert the secondary amines into their carbamate derivatives, followed by hydrogen peroxide addition to produce the corresponding tertiary amine oxides. The resulting derivatives exhibited rich fragmentation patterns, enabling improved structural elucidation
    用于鉴别滥用药物和药用药物的临床毒理学分析方法的需求正在稳步增加。通过 GC-EI-MS 和 LC-ESI-MS/MS 对氨基酰胺类局部麻醉药物及其主要代谢物的结构解析具有很大的分析挑战。这些化合物仅/大部分表现出代表含胺残基的碎片/产物离子,而芳族酰胺部分仍未确定。当需要区分此类化合物的位置异构体时,这项任务变得更加复杂。在这里,我们报告了一种衍生化程序的开发,用于局部麻醉药物及其在水和尿液中具有叔胺和仲胺的代谢物的混合物的分化和结构解析。开发了一种基于环境温度下两个连续“小瓶”瞬时衍生过程随后进行 LC-ESI-MS/MS 分析的方法。2,2,2-三氯-1,1-二甲基乙基氯甲酸酯(TCDMECF)用于选择性地将仲胺转化为其氨基甲酸酯衍生物,然后加入过氧化氢以产生相应的叔胺氧化物。由此产生的衍生物表现出丰富的碎片模式,能够改进原始化合物的结构解析。所开发的方法成功应用于丙胺卡因及其四种位
  • QUATERNARY AMMONIUM SALT COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    申请人:WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    公开号:US20210107872A1
    公开(公告)日:2021-04-15
    A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.
    化合物在公式I中显示,可以是药学上可接受的盐的形式,或立体异构体,或溶剂合物,或前药,或代谢物。该化合物作用迅速,单剂量后具有长时间的局部麻醉效果,感觉神经阻滞时间大于运动神经阻滞时间,既具有长效局部麻醉效果又具有选择性局部麻醉效果,显著减少了QX314和QX314组分以及具有表面活性剂结构特征的季铵盐化合物的副作用,并且更安全。本发明的公式I的化合物及其药学上可接受的盐可用于制备具有长效局部麻醉效果和选择性局部麻醉效果的药物。
  • [EN] MEANS AND METHODS FOR THE N-DEALKYLATION OF AMINES<br/>[FR] MOYENS ET PROCÉDÉS DE N-DÉSALKYLATION D'AMINES
    申请人:UNIV GRONINGEN
    公开号:WO2017179976A1
    公开(公告)日:2017-10-19
    The invention relates to improved means and methods for N- dealkylation of alkylated amines. Provided is a method for the catalytic N- dealkylation of an N-alkylated amine substrate, comprising incubating said amine substrate in a suitable solvent in the presence of a nanoporous gold (NPG) surface and allowing for the formation of an N-dealkylation product. Also provided is a reaction mixture comprising an N-alkylated amine substrate in a suitable solvent and a NPG surface.
    本发明涉及改进的N-脱烷基化烷基化胺的手段和方法。提供了一种催化N-脱烷基化N-烷基化胺底物的方法,包括在适合的溶剂中培养所述胺底物,并在纳米多孔金(NPG)表面存在下,允许形成N-脱烷基化产物。还提供了一种反应混合物,包括适合的溶剂中的N-烷基化胺底物和NPG表面。
  • 一种芳香类化合物、制备方法及在药物中的应用
    申请人:四川道珍科技有限公司
    公开号:CN113214107B
    公开(公告)日:2022-03-18
    一种芳香类化合物,该类化合物可在局部产生持久的神经阻滞作用,产生镇痛、止痒等效果,可用于长效局部麻醉药物、局部镇痛药物和止痒药物的制备。
  • Preparation of human drug metabolites using fungal peroxygenases
    作者:Marzena Poraj-Kobielska、Matthias Kinne、René Ullrich、Katrin Scheibner、Gernot Kayser、Kenneth E. Hammel、Martin Hofrichter
    DOI:10.1016/j.bcp.2011.06.020
    日期:2011.10
    organic chemists. Here we report that aromatic peroxygenases (APOs; EC 1.11.2.1) secreted by the agaric fungi Agrocybe aegerita and Coprinellus radians catalyzed the H(2)O(2)-dependent selective monooxygenation of diverse drugs, including acetanilide, dextrorphan, ibuprofen, naproxen, phenacetin, sildenafil and tolbutamide. Reactions included the hydroxylation of aromatic rings and aliphatic side chains
    通过选择性单加氧合成羟基化和O-或N-去烷基化的人类药物代谢产物(HDM)对于合成有机化学家而言仍然是一项艰巨的任务。在这里我们报告说,由琼脂真菌Agrocybe aegerita和Coprinellus radians分泌的芳香过氧化物酶(APOs; EC 1.11.2.1)催化H(2)O(2)依赖的选择性单氧合作用的多种药物,包括对乙酰苯胺,右旋糖酐,布洛芬,萘普生,非那西丁,西地那非和甲苯磺丁酰胺。反应包括芳环和脂族侧链的羟基化,以及O-和N-脱烷基,根据所使用的特定APO表现出不同的区域选择性。充其量,可以以大于80%的产率和高达99%的异构体纯度获得所需的HDM。甲苯磺丁酰胺的氧化,乙苯胺和卡马西平在H(2)(1)(8)O(2)的存在下导致(1)(8)O几乎完全掺入相应的产物中,因此确定这些反应是过氧化反应。非那西丁-d(1)的脱乙基显示观察到的分子内氘同位素效应[(k(H)/ k(D))(obs)]为3
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物